BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 8, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Oct. 24, 2023

Oct. 24, 2023
Biopharmas raising money in public or private financings, including: Cargo, Coeptis, Dermbiont, Ensysce, Invea, Lipella, Lygenesis, Orbimed, Ultragenyx.
Read More
Science and medicine icons with head made of computer code

Phasev raises $15M for machine learning tool that optimizes clinical trials

Oct. 24, 2023
By Shani Alexander
Phasev Inc. has raised $15 million in a funding round that will allow the company to further develop its machine learning (ML) technology that aims to revolutionize clinical trial design, execution and analysis. The funding round was led by Viola Ventures and Exor Ventures and included participation from Lionbird and a group of prominent angel investors.
Read More

Financings for Oct. 24, 2023

Oct. 24, 2023
Med-tech firms raising money in public or private financings, including: Orbimed.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Med-tech firms raising money in public or private financings, including: Aurora.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Biopharmas raising money in public or private financings, including: Aligos, Applied Molecular Transport, Cyclo, Harpoon.
Read More

Abivax gains US listing, pads coffers with $236M in Nasdaq IPO

Oct. 20, 2023
By Jennifer Boggs
Abivax SA’s debut on the U.S. market received a somewhat chilly reception Oct. 20, as the firm priced on the low end of its proposed range and ended the first day of trading in the red. But the company managed to pull in about $235.8 million in gross proceeds, the majority of which will support late-stage efforts for obefazimod, an oral candidate with a novel mechanism of action it hopes to advance in the lucrative inflammatory bowel disease space.
Read More

Financings for Oct. 20, 2023

Oct. 20, 2023
Biopharmas raising money in public or private financings, including: Arcutis, Adial, Talaris, Tourmaline.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Biopharmas raising money in public or private financings, including: Abivax, Ultragenyx.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Med-tech firms raising money in public or private financings, including: Evident Vascular, Oxford Nanopore, Vitatek.
Read More

Financings for Oct. 18, 2023

Oct. 18, 2023
Biopharmas raising money in public or private financings, including: Actym, Ambrx, Celcuity, Ultragenyx.
Read More
Previous 1 2 … 240 241 242 243 244 245 246 247 248 … 670 671 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 7, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing